CD274 and neoplasm: O’Connell et al. [100] analyzed peripheral blood and paired tumor biopsy samples from patients treated with eganelisib (a PI3K-γ inhibitor) in combination with atezolizumab (a PD-L1 inhibitor) and nab-paclitaxel in the MARIO-3 clinical trial, revealing systemic immune activation and spatial heterogeneity within the TME following treatment.